BioSpace News Archive

No cases of inflammation observed after 12 months with Phase 3 formulation of pegcetacoplan in patients with advanced geographic atrophy (GA)

Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, released an update on the impact of COVID-19 on the Company’s business, the measures it has put in place, accordingly, and its long-term strategy.

Decipher Biosciences announced that patients with the molecular subtype Basal Claudin Low, identified by the Decipher Bladder test and studied in the PURE-01 clinical trial, received the most benefit in progression-free survival from neoadjuvant KEYTRUDA immunotherapy in patients with muscle-invasive bladder cancer.

Forma Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced the appointment of David N. Cook, Ph.D., to the leadership team as senior vice president and chief scientific officer.

Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its first quarter 2020 update and financial results on Tuesday, May 5 at 4:30 p.m. ET..

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020.

Data from Phase 3 clinical trial demonstrate statistically significant effect achieved at all pre-specified primary endpoints

Innate Pharma SA announced that the first patient was dosed in a randomized, double-blind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab, in COVID-19 patients with severe pneumonia.

R-Pharm JSC and Cromos Pharma announced that it has randomized the first patients into a clinical trial evaluating Olokizumab and RPH-104 in patients with severe COVID-19 infection.

FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants aged 1-7 months after 12 months of treatment